Global Thyroid Gland Disorder Treatment Market to 2025 by Disease Type, Drug Type, Route of Administration, and Distribution/Sales Channel - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Aug 8, 2018--The “Thyroid Gland Disorder Treatment Market by Disease Type, Drug Type, Route of Administration, and Distribution/Sales Channel - Global Opportunity Analysis and Industry Forecast, 2017-2025” report has been added to ResearchAndMarkets.com’s offering.
The global thyroid gland disorder market was valued at $2,057 million in 2017, and is estimated to reach $2,771 million at a CAGR of 3.8% from 2018 to 2025.
North America was the highest contributor to the thyroid gland disorder treatment market in 2017; however, Asia-Pacific is expected to witness the highest growth during the forecast period.
The major factors that drive the growth of the thyroid gland disorder market include increase in incidence of thyroid gland disorders, development of effective combination thyroid disorders drug therapies, and increase in number of disease awareness programs in developing regions.
However, side effects of the medication and stringent government regulations limit the market growth. Conversely, availability of large pool of undiagnosed patients due to asymptomatic nature of thyroid disorders in the emerging economies are anticipated to provide numerous opportunities for the market growth during the forecast period.
Among the disease type, the hypothyroidism segment occupied the largest share, and is anticipated to continue its dominance during the forecast period, owing to the high prevalence of iodine deficiency population worldwide, and is the most commonly occurring thyroid disorder.
Among the distribution channel, the wholesaler or distributor segment occupied the largest share. However, mail-order pharmacy is the fastest growing segment as these services help customers save money and convenience.
Among the route of administration, the oral segment occupied the largest share as most of the medications available in the market are in the form of tablets or pills that can easily be administered by the patients.
Companies ProfiledAbbott Laboratories AbbVie Inc. Allergan Plc GlaxoSmithKline Plc Lannett Company Inc. Merck & Co. Inc. Mylan N.V. Novartis AG Pfizer Inc. RLC LABS Inc.
For more information about this report visit https://www.researchandmarkets.com/research/2xdr9j/global_thyroid?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180808005760/en/
Laura Wood, Senior Manager
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Endocrine and Metabolic Disorders Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 08/08/2018 03:59 PM/DISC: 08/08/2018 03:59 PM